BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a promising method to increase resectability rates of liver tumors. Little has been published about oncological results so far. This report describes clinical evidence regarding a possible effect of ALPPS on tumor recurrence. METHODS: Ten ALPPS procedures were performed for otherwise non-resectable colorectal liver metastases. Seven of these ten patients had a follow-up of at least 3 months and were analyzed for tumor recurrence. RESULTS: Six of these seven patients had tumor recurrence to the liver. Three of seven patients presented with lung metastases, occurring earlier than liver metastases in two of three cases. One patient with a follow-up of 3 months had no visible recurrent disease, but increasing carcinoembryonic antigen levels. CONCLUSIONS: The patient group operable only through ALPPS is at high risk for recurrence and early tumor progression. Still, this new method is the only chance for an oncological treatment strategy including a surgical approach and possibly better outcome.
BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a promising method to increase resectability rates of liver tumors. Little has been published about oncological results so far. This report describes clinical evidence regarding a possible effect of ALPPS on tumor recurrence. METHODS: Ten ALPPS procedures were performed for otherwise non-resectable colorectal liver metastases. Seven of these ten patients had a follow-up of at least 3 months and were analyzed for tumor recurrence. RESULTS: Six of these seven patients had tumor recurrence to the liver. Three of seven patients presented with lung metastases, occurring earlier than liver metastases in two of three cases. One patient with a follow-up of 3 months had no visible recurrent disease, but increasing carcinoembryonic antigen levels. CONCLUSIONS: The patient group operable only through ALPPS is at high risk for recurrence and early tumor progression. Still, this new method is the only chance for an oncological treatment strategy including a surgical approach and possibly better outcome.
Authors: Marcello Donati; Gregor A Stavrou; Francesco Basile; Salvatore Gruttadauria; Klaus J Niehaus; Karl J Oldhafer Journal: Ann Surg Date: 2012-09 Impact factor: 12.969
Authors: N Kokudo; K Tada; M Seki; H Ohta; K Azekura; M Ueno; K Ohta; T Yamaguchi; T Matsubara; T Takahashi; T Nakajima; T Muto; T Ikari; A Yanagisawa; Y Kato Journal: Hepatology Date: 2001-08 Impact factor: 17.425
Authors: Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt Journal: Ann Surg Date: 2012-03 Impact factor: 12.969
Authors: Adel Abulkhir; Paolo Limongelli; Andrew J Healey; Osama Damrah; Paul Tait; James Jackson; Nagy Habib; Long R Jiao Journal: Ann Surg Date: 2008-01 Impact factor: 12.969
Authors: Alan W Hemming; Alan I Reed; Richard J Howard; Shiro Fujita; Steven N Hochwald; James G Caridi; Irvin F Hawkins; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2003-05 Impact factor: 12.969
Authors: Junichi Shindoh; Jean-Nicolas Vauthey; Giuzeppe Zimmitti; Steven A Curley; Steven Y Huang; Armeen Mahvash; Sanjay Gupta; Michael J Wallace; Thomas A Aloia Journal: J Am Coll Surg Date: 2013-04-28 Impact factor: 6.113
Authors: Sven A Lang; Martin Loss; Volker Benseler; Gabriel Glockzin; Hans J Schlitt Journal: Langenbecks Arch Surg Date: 2015-02-18 Impact factor: 3.445
Authors: Martin Zeile; Artur Bakal; Jan E Volkmer; Gregor A Stavrou; Philip Dautel; Jan Hoeltje; Axel Stang; Karl J Oldhafer; Roland Brüning Journal: Br J Radiol Date: 2016-10-12 Impact factor: 3.039
Authors: T F Ulmer; C de Jong; A Andert; P Bruners; C M Heidenhain; W Schoening; M Schmeding; U P Neumann Journal: World J Surg Date: 2017-01 Impact factor: 3.352